## Glenmark – Recall of arformoterol inhalation solution

- On April 25, 2022, Glenmark announced a consumer-level recall of several lots of arformoterol inhalation solution due to a lack of assurance of product sterility discovered after a review of the manufacturing facility's microbiology laboratory controls and processes.

| Product Description | NDC# | Lot# (Expiration Date) |
|---|---|---|
| Arformoterol 15 mcg/ 2 mL inhalation solution | 68462-833-35 | 30210041 (3/31/2023); 30210045 (3/31/2023); 30210046 (4/30/2023); 30210050 (4/30/2023); 30210051 (4/30/2023); 30210058 (4/30/2023) |
| | 68462-833-65 | 30210042 (3/31/2023); 30210047 (4/30/2023); 30210048 (4/30/2023); 30210052 (4/30/2023); 30210053 (4/30/2023); 30210054 (4/30/2023); 30210059 (4/30/2023); 30210060 (4/30/2023); 30210061 (4/30/2023); 30210062 (4/30/2023); 30210063 (4/30/2023); 30210064 (5/31/2023) |

- Arformoterol inhalation solution is indicated for the long-term, twice daily maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
- Anyone with an existing inventory of the recalled product should stop distribution and quarantine the product immediately.
- Patients should contact their physician or health care provider if they have experienced any problems that may be related to taking or using the recalled arformoterol.
- Contact Qualanex by phone at **1-888-504-2012** or by email at **recall@qualanex.com** for return information and for more information about the recall.